Benzopyran sulfonamides as KV1.5 potassium channel blockers

John Lloyd; Karnail S Atwal; Heather J Finlay; Michael Nyman; Tram Huynh; Rao Bhandaru; Alexander Kover; Joan Schmidt; Wayne Vaccaro; Mary Lee Conder; Tonya Jenkins-West; Paul Levesque

doi:10.1016/j.bmcl.2007.04.020

Benzopyran sulfonamides as KV1.5 potassium channel blockers

Bioorg Med Chem Lett. 2007 Jun 15;17(12):3271-5. doi: 10.1016/j.bmcl.2007.04.020. Epub 2007 Apr 10.

Authors

John Lloyd¹, Karnail S Atwal, Heather J Finlay, Michael Nyman, Tram Huynh, Rao Bhandaru, Alexander Kover, Joan Schmidt, Wayne Vaccaro, Mary Lee Conder, Tonya Jenkins-West, Paul Levesque

Affiliation

¹ Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 5400, Princeton, NJ 08543-5400, USA. john.lloyd@bms.com

PMID: 17462888
DOI: 10.1016/j.bmcl.2007.04.020

Abstract

K(V)1.5 blockers have the potential to be atrium-selective agents for treatment of atrial fibrillation. The benzopyrans provide a template for the synthesis of potent and selective K(V)1.5 blockers.

MeSH terms

Atrial Fibrillation / drug therapy*
Atrial Function / drug effects*
Atrial Function / physiology
Benzopyrans / chemistry
Benzopyrans / pharmacology*
Kv1.5 Potassium Channel / drug effects*
Kv1.5 Potassium Channel / metabolism
Models, Chemical
Potassium Channel Blockers / chemical synthesis
Potassium Channel Blockers / pharmacology*
Sulfonamides / chemistry
Sulfonamides / pharmacology*

Substances

Benzopyrans
Kv1.5 Potassium Channel
Potassium Channel Blockers
Sulfonamides